CompletedNCT03953833B003-101Updated Sep 14, 2023

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

A Phase 1 interventional study of Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003. in HER2-positive Breast Cancer, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Completed at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 30
Allocation: Not applicable
Ages: 18 Years to 75 Years
Sex: Female

Study summary

To assess the safety and tolerability characteristics of B003 in HER2-positive patients with recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) is assessed and the maximum tolerated dose (MTD) is explored.

Conditions studied

HER2-positive Breast Cancer

Browse trials for

Breast Neoplasms 12,544

Keywords

DLT
MTD
Safety
tolerability
HER2-positive
Recombinant Humanized Anti-HER2 Monoclonal Antibody

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 30 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Shanghai Pharmaceuticals Holding Co., Ltd is the lead sponsor of 35 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 75 Years
Sexes eligible: Female
Accepts healthy volunteers: No

Inclusion criteria

18 years old ≤ age ≤ 75 years old, female;
Histological or cytologically confirmed recurrent or metastatic breast cancer,Anti-HER2 treatment failure for recurrent or metastatic disease;
According to RECIST v 1.1, patients with measurable and/or unmeasurable lesions: 1) Patients with bone metastases, as long as the bone metastases have never received radiotherapy, and the primary tumours are available for HER2 detection and Biomarker analysis, which can be enrolled.
Female patients of childbearing age, patients and/or their partners should agree to use a highly effective non-hormonal contraceptive method or two effective non-hormonal contraceptive methods. Continue to use the appropriate contraceptive measures during the study period and at least 6 months after the last dose.
- Electrocorticography (ECOG) physical state (PS) is 0-1 points;
- Expected to survive for more than 3 months;
- Understand and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

Previously received T-DM1 or same type of drug for treatment, previously used trastuzumab within 3 months before the trial, previously involved in other clinical trials within 4 weeks before the trial.
Known to be allergic to the study drug or its components;
Have received any anti-cancer trial medication within 28 days prior to the start of the trial;
Have received hormone treatment within 7 days before the trial.
Hematological toxicity caused by previous treatment CTCAE ≥ 2 persistence (except hemoglobin) (NCI-CTCAE version 4.03);
A third gap effusion with clinical symptoms that cannot be controlled by drainage or other methods.
The cumulative dose of anthracyclines used meets the following values: doxorubicin or liposomal doxorubicin >450 mg/m2; epirubicin >900 mg/m2; mitoxantrone >120 mg/m2; Idarubicin > 90 mg/m2. If another anthracycline or more than one anthracycline is used, the cumulative dose should not exceed the equivalent dose of doxorubicin 500mg/m2
Patients with other malignant tumors (cervical cancer of StageI B or lower that has been cured, non-invasive basal cells or squamous cell skin cancer, complete remission (CR) > 10 years of malignant melanoma, Except for other malignant tumors with complete remission (CR) > 5 years);
Laboratory abnormalities: 1) Neutrophil count \<1.5×109/L, 2) Platelet count \<100×109/L, 3) Hemoglobin \<90 g/L, 4) Total bilirubin > 1.5 x upper limit of normal (ULN), 5) Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 × ULN, 6) Serum creatinine >1.5×ULN or creatinine clearance \<50 mL/min;
Currently suffering from a serious and uncontrollable systemic disease (eg, clinically significant cardiovascular disease, lung disease, active infection, or metabolic disease);
Have a tendency to hemorrhage and thrombosis: 1) Any CTCAE 4.03 Level 2 bleeding event occurred within 2 months prior to screening, or CTCAE 4.03 Level 3 and above bleeding events within the first 6 months of screening; 2) A history of gastrointestinal bleeding within 6 months prior to screening or a clear tendency to gastrointestinal bleeding. Such as: esophageal varices with bleeding risk, local active ulcer lesions, fecal occult blood + +; 3) There is currently active bleeding or coagulopathy (PT>16s, activated partial thromboplastin time >43s, thrombin time)>21s, INR≥2.3, all of which need to be ruled out), have bleeding tendency or are receiving thrombolysis or anti- Coagulation therapy; 4) Patients need anticoagulant therapy with warfarin or heparin; 5) Patients need long-term antiplatelet therapy (eg aspirin, clopidogrel); 6) Thrombotic or embolic events in the past 6 months, such as: cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism;
History of severe cardiovascular disease: 1) According to NYHA (New York Heart Association), current cardiac function classification: grade III or IV; 2) There is currently congestive heart failure and New York Heart Association cardiac function grade II and above; 3) A history of unstable angina or myocardial infarction within 6 months prior to screening; 4) There are currently arrhythmias requiring therapeutic intervention (patients taking beta-blockers or digoxin can be enrolled); 5) According to the current two-dimensional echocardiographic results, the left ventricular ejection fraction (LVEF) is \<50%; 6) Have a history of LVEF falling below 40%, or have had symptomatic congestive heart failure when treated with anti-HER2; 7) There is currently poorly controlled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg); 8) Cardiac troponin I ≥ 0.2 ng/mL;
There is a history of moderate or severe dyspnea at rest due to advanced malignancies or their complications or severe pulmonary primary disease, or current continuous oxygen therapy is required;
Symptomatic brain metastases, depression or schizophrenia;
History of immunodeficiency, including: HIV-positive, or other acquired, congenital immunodeficiency disease, or a history of organ transplantation;
Hepatitis B (HBsAg and / or HBcAb positive, and peripheral blood hepatitis B virus DNA titer test results beyond the normal range of the research center), and / or hepatitis C patients;
Alcohol dependence, hormone dependence or drug abusers;
The investigator believes that there are other factors that are not suitable for the trial.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 30 participants (actual)

Study arms

Experimental
recombinant anti-HER2 humanized monoclonal antibody conjugate
Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R \& D code: B003 Drug Type : Biological Products
Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.

Interventions

BiologicalRecombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage. Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle.

What researchers measure

Primary outcomes

Maximum Tolerated Dose
The maximum tolerated dose (MTD) is operationally defined in toxicology as the highest daily dose of a chemical that does not cause overt toxicity in subjects
Time frame: through study completion, an average of 2 years
Dose-Limiting Toxicity
Some of the major toxic side effects are the main reasons limiting the continued increase in the dose of chemotherapy drugs, which are the dose-limiting toxicity of chemotherapy drugs.
Time frame: From day 1 to day 21 of treatment
Immunogenicity assessment
Sample positive rate and Individual positive rate of Anti-drug antibody(ADA)
Time frame: through study completion, an average of 2 years
Titer of ADA positive sample
a test to determine the level or degree of ADA positive samples and analyse the effect on the plasma concentration.
Time frame: through study completion, an average of 2 years
Pharmacokinetics measurement A
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. Peak Plasma Time (Tmax)
Time frame: through study completion, an average of 2 year
Pharmacokinetics measurement B
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. Peak Plasma Concentration (Cmax)
Time frame: through study completion, an average of 2 year
Pharmacokinetics measurement C
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. half-life time
Time frame: through study completion, an average of 2 year
Pharmacokinetics measurement D
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. Mean Residence Time( MRT)
Time frame: through study completion, an average of 2 year
Pharmacokinetics measurement E
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. Area under the plasma concentration versus time curve (AUC)
Time frame: through study completion, an average of 2 year
Pharmacokinetics measurement F
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. elimination rate constant
Time frame: through study completion, an average of 2 year
Pharmacokinetics measurement G
According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded. clearance rate(CL/F)
Time frame: through study completion, an average of 2 year
Therapeutic Efficacy A
Objective Remission Rate (ORR): to be defined as the percentage of patients with complete response or partial response. Patients with CR or PR for the first evaluation will be confirmed after 4weeks. Patients without any evaluations are regarded as none-response.
Time frame: from date of start from the infusion of the first subject until the date after two treatments of the last subject, assessed up to 14 months.
Therapeutic Efficacy B
Disease Control rate(DCR): to be defined as the percentage of patients with complete response, partial response or stable disease.
Time frame: from date of start from the infusion of the first subject until the date after two treatments of the last subject, assessed up to 14 months.
Therapeutic Efficacy C
Duration of response(DOR): to be defined as the duration from the first evaluation time when the patient has CR or PR to the first evaluation time when the patient has disease progression or death.
Time frame: from the date when he patient has CR or PR to the first evaluation until the date when the patient has disease progression or death, assessed up to 14 months.
Therapeutic Efficacy D
Progression-free survival:to be defined as the duration from the time of first infusion to the first recording time when the patient has disease progression or death.
Time frame: from the date when he patient has CR or PR to the first evaluation until the date when the patient has disease progression or death, assessed up to 14 months.

Study locations

1 site

West China Hospital of Sichuan University
Chengdu, Sichuan, China

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03953833
Lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Responsible party: Sponsor
First posted: May 17, 2019
Start date: Apr 1, 2019
Primary completion: Jan 13, 2023
Completion: Jan 13, 2023
Last update: Sep 14, 2023

Study contacts

Yu Jiang

principal investigator · West China Hospital

Yongsheng Wang

principal investigator · West China Hospital

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breast Neoplasms→

Other studies from this sponsor

Shanghai Pharmaceuticals Holding Co., Ltd

Start the discussion